Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8748861rdf:typepubmed:Citationlld:pubmed
pubmed-article:8748861lifeskim:mentionsumls-concept:C0032105lld:lifeskim
pubmed-article:8748861lifeskim:mentionsumls-concept:C0021027lld:lifeskim
pubmed-article:8748861lifeskim:mentionsumls-concept:C0018946lld:lifeskim
pubmed-article:8748861lifeskim:mentionsumls-concept:C0242485lld:lifeskim
pubmed-article:8748861lifeskim:mentionsumls-concept:C0441889lld:lifeskim
pubmed-article:8748861lifeskim:mentionsumls-concept:C0475208lld:lifeskim
pubmed-article:8748861lifeskim:mentionsumls-concept:C0032172lld:lifeskim
pubmed-article:8748861lifeskim:mentionsumls-concept:C1522492lld:lifeskim
pubmed-article:8748861lifeskim:mentionsumls-concept:C0205191lld:lifeskim
pubmed-article:8748861pubmed:issue1-2lld:pubmed
pubmed-article:8748861pubmed:dateCreated1996-9-30lld:pubmed
pubmed-article:8748861pubmed:abstractTextIn order to estimate the contribution of platelet-activating factor (PAF) to the formation of chronic subdural haematomas (CSH), we measured plasma PAF and anti-PAF antibody levels in head-injured patients with and without CSH and normal volunteers. Plasma PAF and anti-PAF IgG levels were higher in patients with CSH than in patients without CSH or in normal volunteers. Furthermore, plasma PAF and anti-PAF IgG levels increased in a time-dependent manner over the first 35 days following head injury. These data suggest that PAF may be involved in the generation of CSH.lld:pubmed
pubmed-article:8748861pubmed:languageenglld:pubmed
pubmed-article:8748861pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8748861pubmed:citationSubsetIMlld:pubmed
pubmed-article:8748861pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8748861pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8748861pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8748861pubmed:statusMEDLINElld:pubmed
pubmed-article:8748861pubmed:issn0001-6268lld:pubmed
pubmed-article:8748861pubmed:authorpubmed-author:NojimaSSlld:pubmed
pubmed-article:8748861pubmed:authorpubmed-author:EndoSSlld:pubmed
pubmed-article:8748861pubmed:authorpubmed-author:HayashiNNlld:pubmed
pubmed-article:8748861pubmed:authorpubmed-author:TakakiMMlld:pubmed
pubmed-article:8748861pubmed:authorpubmed-author:HirashimaYYlld:pubmed
pubmed-article:8748861pubmed:authorpubmed-author:KarasawaKKlld:pubmed
pubmed-article:8748861pubmed:issnTypePrintlld:pubmed
pubmed-article:8748861pubmed:volume137lld:pubmed
pubmed-article:8748861pubmed:ownerNLMlld:pubmed
pubmed-article:8748861pubmed:authorsCompleteYlld:pubmed
pubmed-article:8748861pubmed:pagination15-8lld:pubmed
pubmed-article:8748861pubmed:dateRevised2009-11-11lld:pubmed
pubmed-article:8748861pubmed:meshHeadingpubmed-meshheading:8748861-...lld:pubmed
pubmed-article:8748861pubmed:meshHeadingpubmed-meshheading:8748861-...lld:pubmed
pubmed-article:8748861pubmed:meshHeadingpubmed-meshheading:8748861-...lld:pubmed
pubmed-article:8748861pubmed:meshHeadingpubmed-meshheading:8748861-...lld:pubmed
pubmed-article:8748861pubmed:meshHeadingpubmed-meshheading:8748861-...lld:pubmed
pubmed-article:8748861pubmed:meshHeadingpubmed-meshheading:8748861-...lld:pubmed
pubmed-article:8748861pubmed:meshHeadingpubmed-meshheading:8748861-...lld:pubmed
pubmed-article:8748861pubmed:meshHeadingpubmed-meshheading:8748861-...lld:pubmed
pubmed-article:8748861pubmed:meshHeadingpubmed-meshheading:8748861-...lld:pubmed
pubmed-article:8748861pubmed:meshHeadingpubmed-meshheading:8748861-...lld:pubmed
pubmed-article:8748861pubmed:meshHeadingpubmed-meshheading:8748861-...lld:pubmed
pubmed-article:8748861pubmed:meshHeadingpubmed-meshheading:8748861-...lld:pubmed
pubmed-article:8748861pubmed:meshHeadingpubmed-meshheading:8748861-...lld:pubmed
pubmed-article:8748861pubmed:meshHeadingpubmed-meshheading:8748861-...lld:pubmed
pubmed-article:8748861pubmed:year1995lld:pubmed
pubmed-article:8748861pubmed:articleTitlePlatelet-activating factor (PAF) and the formation of chronic subdural haematoma. Measurement of plasma PAF levels and anti-PAF immunoglobulin titers.lld:pubmed
pubmed-article:8748861pubmed:affiliationDepartment of Neurosurgery, Toyama Medical and Pharmaceutical University, Japan.lld:pubmed
pubmed-article:8748861pubmed:publicationTypeJournal Articlelld:pubmed